ReviewNature reviews. Immunology2022
The germinal centre B cell response to SARS-CoV-2.
Review in Nature reviews. Immunology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 188 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
188 citing papers in PubMed.
- HIV-1 envelope trimer vaccine induces sex-associated differences in antibody responses: a phase 1 clinical trial.Nature communications · 2025Trial
- Trivalent recombinant protein vaccine induces cross-neutralization against XBB lineage and JN.1 subvariants: preclinical and phase 1 clinical trials.Nature communications · 2024Trial
- Vaccination Schedule and Age Influence Impaired Responsiveness to Hepatitis B Vaccination: A Randomized Trial in Central Asia.Pathogens (Basel, Switzerland) · 2024Trial
- Acceptance of the COVID-19 Booster Vaccine Amid the Omicron JN.1 Surge in Southern Bangladesh: A Comparative Analysis of Rural-Urban Disparities.Risk analysis : an official publication of the Society for Risk Analysis · 2026Observational
- Immunological Mechanisms and Machine Learning Applications in Post-COVID-19 Syndrome: A Narrative Review.Microorganisms · 2026Article
- A glycan-based adjuvant expands the breadth and duration of protection of mRNA-based vaccines.Nature immunology · 2026Article
- Long-Term Durability and Dynamics of Anti-S-RBD IgG Response in Healthcare Workers: A Comparative Analysis of Homologous and Heterologous SARS-CoV-2 Vaccination Schedules in a 1-Year Serial Cross-Sectional Study.Medical science monitor : international medical journal of experimental and clinical research · 2026Article
- Antibody Transcytosis and Neutralizing Activity in Respiratory Epithelial Cells.bioRxiv : the preprint server for biology · 2026Article
- Intranasal vaccine combining adenovirus and trimeric subunit protein provides superior immunity against SARS-CoV-2 Omicron variant.Nature biomedical engineering · 2026Article
- Immunological memory to vaccines.Immunity · 2026Review
- Homologous MVA and heterologous DREP/MVA vaccine regimens induce robust and durable immune responses against SARS-CoV-2.Scientific reports · 2026Article
- Rapid and potent induction of protective mucosal immunity against SARS-CoV-2 by an adenovirus-vectored nanoparticle vaccine.Journal of nanobiotechnology · 2026Article
- A new mRNA antigen vaccine induces potent B and T cell responses and in vivo protection against SARS-CoV-2.NPJ vaccines · 2026Article
- Variant-Specific Kinetics of SARS-CoV-2 Anti-Nucleocapsid Antibodies and Household Transmission in Families During Anchestral, Alpha, Delta and Omicron Periods.Life (Basel, Switzerland) · 2026Article
- A new mRNA antigen vaccine induces potent B and T cell responses andbioRxiv : the preprint server for biology · 2026Article
- Programmable trivalent nanocage vaccine confers durable cross-species protection against Bordetella bronchiseptica infection.Journal of nanobiotechnology · 2026Article
- CD25 modulation enhances broadly neutralizing antibody response of SARS-CoV-2 subunit vaccine.Communications biology · 2026Article
- Extrafollicular and other non-germinal center B cell responses.Journal of immunology (Baltimore, Md. : 1950) · 2026Review
- Direct Cytoplasmic Transcription and Trimeric RBD Design Synergize to Enhance DNA Vaccine Potency Against SARS-CoV-2.Pharmaceutics · 2026Article
- Rapid immunization and antibody redesign platform discovers broadly neutralizing antibodies against non-immunized SARS-CoV-2 variant.Molecular therapy : the journal of the American Society of Gene Therapy · 2026Article
128 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
The germinal centre (GC) response is critical for the generation of affinity-matured plasma cells and memory B cells capable of mediating long-term protective immunity. Understanding whether severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection or vaccination elicits a GC response has profound implications for the capacity of responding B cells to contribute to protection against infection. However, direct assessment of the GC response in humans remains a major challenge. Here we summarize emerging evidence for the importance of the GC response in the establishment of durable and broad immunity against SARS-CoV-2 and discuss new approaches to modulate the GC response to better protect against newly emerging SARS-CoV-2 variants. We also discuss new findings showing that the GC B cell response persists in the draining lymph nodes for at least 6 months in some individuals following vaccination with SARS-CoV-2 mRNA-based vaccines.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.